Akoya Biosciences Receivables

Akoya Biosciences (AKYA) currently reports a receivables of $12M as of March 2025. That compares with $13M in the prior-year period — down 12.8% year over year. Use the charts on this page to explore Akoya Biosciences's receivables history and peer comparisons.

Akoya Biosciences's receivables decreased from $13M to $12M — a 12.8% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Akoya Biosciences reported $12M in receivables as of March 2025. That compares with $13M in the prior-year period — down 12.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $12M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Akoya Biosciences, and consider following AKYA for alerts when major investors trade the stock.

Akoya Biosciences is classified in the Healthcare sector. On receivables, it currently shows $12M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AKYA with unrelated industries.